Banjaree S et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(12):1721-31. Abstract

DiSilvestro P et al. Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial. ESMO 2022;Abstract 517O.

Gonzalez-Martin A et al. PRIMA/ENGOT-OV26/GOG-3012 Study: Updated long-term PFS and safety. IGCS 2022;Abstract S005/1753.

Kristeleit RS et al. Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase III study. SGO 2021;Abstract 1.

Monk BJ et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;40(34):3952-64. Abstract

Oza AM et al. Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation. ESMO 2022;Abstract 518O.

Pujade-Lauraine E et al. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (oc) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-28 trial. ESMO 2022;Abstract LBA33.

Ray-Coquard I et al. Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). ESMO 2022;Abstract LBA29.

Selle F et al. OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts. ASCO 2022;Abstract 5558.